Cell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Pharmacology
• Drug Discovery

Background:

• Tuberculosis (TB) treatment requires new combination regimens to improve efficacy and reduce toxicity.
• Identifying synergistic drug combinations is crucial for shortening treatment duration and minimizing adverse effects.

Purpose of the Study:

• To investigate the mechanism of synergy between cell wall inhibitors and rifampicin in Mycobacterium tuberculosis.
• To determine if increased drug accumulation is a key factor in synergistic activity.

Main Methods:

• Utilized a fluorescent rifampicin conjugate to track drug accumulation within bacterial cells.
• Quantified rifampicin accumulation in response to co-administration with cell wall inhibitors.

Main Results:

• Synergy between cell wall inhibitors and rifampicin was directly correlated with increased intracellular accumulation of rifampicin.
• Enhanced rifampicin accumulation was associated with increased bacterial cell permeability.

Conclusions:

• Increased cellular permeability and subsequent rifampicin accumulation are key mechanisms underlying the synergy observed with cell wall inhibitors.
• This mechanistic insight can guide the development of novel, more effective tuberculosis combination therapies.